Erythropoietin and Acute Renal Failure

Seminars in Nephrology

Volumn 26, Issue 4, 2006, Pages 325-331

  Sharples, Edward J ^a   Yaqoob, Muhammad M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

acute renal failure

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BRAIN; BRAIN ISCHEMIA; CELL DEATH; CELL PROTECTION; CLINICAL PRACTICE; HEART; HEART INFARCTION; HUMAN; IN VIVO STUDY; ISCHEMIA; KIDNEY; KIDNEY FAILURE; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES, PROXIMAL; REPERFUSION INJURY;

EID: 33750875495     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.05.010     Document Type: Article

References (62)

1. Nash K., Hafeez A., and Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 39 (2002) 930-936
2. Zanardo G., Michielon P., Paccagnella A., et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg 107 (1994) 1489-1495
3. Hou S.H., Bushinsky D.A., Wish J.B., et al. Hospital-acquired renal insufficiency: A prospective study. Am J Med 74 (1983) 243-248
4. Herget-Rosenthal S., Marggraf G., Husing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 66 (2004) 1115-1122
5. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005) 1231-1238
6. Levy E.M., Viscoli C.M., and Horwitz R.I. Effect of acute renal failure on mortality. A cohort analysis. JAMA 275 (1996) 1489-1494
7. Chertow G.M., Burdick E., Honour M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16 (2005) 3365-3370
8. Liangos O., Wald R., O'Bell J.W., et al. Epidemiology and outcomes of acute renal failure in hospitalised patients: a national survey. Clin J Am Soc Nephrol 1 (2006) 43-51
9. Hladunewich M.A., Corrigan G., Derby G.C., et al. A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF. Kidney Int 64 (2003) 593-602
10. Hirschberg R., Kopple J., Lipsett P., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 55 (1999) 2423-2432
11. Sutton T.A., Fisher C.J., and Molitoris B.A. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 62 (2002) 1539-1549
12. Lacombe C., and Mayeux P. Biology of erythropoietin. Haematologica 83 (1998) 724-732
13. Miyake T., Kung C.K., and Goldwasser E. Purification of human erythropoietin. J Biol Chem 252 (1977) 5558-5564
14. Lin F.K., Suggs S., Lin C.H., et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82 (1985) 7580-7584
15. Eschbach J.W., Egrie J.C., Downing M.R., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phaseI and II clinical trial. N Engl J Med 316 (1987) 73-78
16. Winearls C.G., Oliver D.O., Pippard M.J., et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2 (1986) 1175-1178
17. Maxwell P.H., Osmond M.K., Pugh C.W., et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44 (1993) 1149-1162
18. Wu H., Liu X., Jaenisch R., et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83 (1995) 59-67
19. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74 (1993) 227-236
20. Spivak J.L., Pham T., Isaacs M., et al. Erythropoietin is both a mitogen and a survival factor. Blood 77 (1991) 1228-1233
21. Maxwell P. HIF-1: An oxygen response system with special relevance to the kidney. J Am Soc Nephrol 14 (2003) 2712-2722
22. Iyer N.V., Kotch L.E., Agani F., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
23. Cai Z., Manalo D.J., Wei G., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108 (2003) 79-85
24. Matsumoto M., Makino Y., Tanaka T., et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 14 (2003) 1825-1832
25. Digicaylioglu M., Bichet S., Marti H.H., et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 92 (1995) 3717-3720
26. Juul S.E., Yachnis A.T., and Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 3 (1998) 235-249
27. Sakanaka M., Wen T.C., Matsuda S., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95 (1998) 4635-4640
28. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19 (1999) 643-651
29. Digicaylioglu M., and Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412 (2001) 641-647
30. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97 (2000) 10526-10531
31. Junk A.K., Mammis A., Savitz S.I., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 99 (2002) 10659-10664
32. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
33. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
34. Westenfelder C., Biddle D.L., and Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55 (1999) 808-820
35. Nemato T., Yokota N., Keane W.F., et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 59 (2001) 246-251
36. Yang C.W., Li C., Jung J.Y., et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17 (2003) 1754-1755
37. Vesey D.A., Cheung C., Pat B., et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19 (2004) 348-355
38. Chatterjee P.K., and Thiemermann C. An in vivo model of ischemia/reperfusion and inflammation of the kidneys of the rat. Methods Mol Biol 225 (2003) 223-237
39. Sharples E.J., Patel N., Brown P., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15 (2004) 2115-2124
40. Moon C., Krawczyk M., Paik D., et al. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther 19 (2005) 243-250
41. Brezis M., and Rosen S. Hypoxia of the renal medulla-its implications for disease. N Engl J Med 332 (1995) 647-655
42. Molitoris B.A., Sandoval R., and Sutton T.A. Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med 30 (2002) S235-S240
43. Basile D.P., Donohoe D., Roethe K., et al. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol 281 (2001) F887-F899
44. Brodsky S.V., Yamamoto T., Tada T., et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol 282 (2002) F1140-F1149
45. Anagnostou A., Lee E.S., Kessimian N., et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87 (1990) 5978-5982
46. Beleslin-Cokic B.B., Cokic V.P., Yu X., et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104 (2004) 2073-2080
47. Scalera F., Kielstein J.T., Martens-Lobenhoffer J., et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16 (2005) 892-898
48. Buemi M., Galeano M., Sturiale A., et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 22 (2004) 169-173
49. Bahlmann F.H., DeGroot K., Duckert T., et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64 (2003) 1648-1652
50. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
51. Patel N.S., Sharples E.J., Cuzzocrea S., et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66 (2004) 983-989
52. Vaziri N.D., Zhou X.J., and Liao S.Y. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266 (1994) F360-F366
53. Bahlmann F.H., Song R., Boehm S.M., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110 (2004) 1006-1012
54. Jaquet K., Krause K., Tawakol-Khodai M., et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64 (2002) 326-333
55. Fishbane S., Ragolia L., Palaia T., et al. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 65 (2004) 452-458
56. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
57. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
58. Fiordaliso F., Chimenti S., Staszewsky L., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102 (2005) 2046-2051
59. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 (2000) 647-657
60. Feldman L., Wang Y., Rhim J.S., et al. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66 (2005) 135-145
61. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
62. Hardee M.E., Kirkpatrick J.P., Shan S., et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 93 (2005) 1350-1355